



FACSIMILE

DATE: March 10, 2005
OFFICIAL PAPER

Please deliver this and the following pages to:

Examiner: **Not Yet Assigned**
U.S.P.T.O. Group Art Unit: **1646**
Telecopier No.: **(703) 746-9195**
U.S. Serial No.: **10/770,380**
Client/Matter No.: **DM-6999/BMS-2594**
Sender's Name: **Deb Wilkinson for Brian J. Hubbard**
Pages to Follow: **4**

If transmission is not complete, please call our Philadelphia Office at (215) 568-3100.

COVER MESSAGE:

OFFICIAL FACSIMILE. PLEASE DELIVER TO EXAMINER IMMEDIATELY.

Attached hereto is/are the following documents:

- 1) Request to Correct Filing Receipt; and
- 2) Copy of Filing Receipt with annotated change.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERY OF THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

WOODCOCK WASHBURN LLP
A Partnership Including Professional Corporations
www.woodcock.com

PHILADELPHIA
One Liberty Place, 46th Floor
Philadelphia, PA 19103
215-568-3100
Fax: 215-568-3439
SEATTLE
999 Third Avenue, Suite 1606
Seattle, WA 98104
206-332-1380
Fax: 206-624-7317

JOB CODE:

193636

DOCKET NO.: DM-6999/BMS-2594

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Rajopadhye, et al.

Application No.: 10/770,380

Filing Date: February 2, 2004

For: Vitronectin Receptor Antagonist Pharmaceuticals

Confirmation No.: 9680


Group Art Unit: 1646

Examiner: Not Yet Assigned

CERTIFICATE OF FACSIMILE TRANSMISSION

DATE: March 10, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING
FACSIMILE TRANSMITTED TO THE PATENT AND
TRADEMARK OFFICE TO FACSIMILE NUMBER (703)
746-9195 ON THE DATE LISTED ABOVE.


Brian J. Hubbard REG. NO. 45,873

Office of Initial Patent Examination
Customer Service Center
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attention:

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a Corrected Filing Receipt is respectfully requested. The requested changes are noted thereon, as well as listed below.
2. There is an error with respect to the following data which is:
 - ☒ incorrectly entered; and/or
 - ☐ omitted.


DOCKET NO.: DM-6999/BMS-2594 - 2 -

PATENT

Error in	Correct data
1. Applicant's name	1.
2. Applicant's address	2.
3. Title	3.
4. Filing Date	4.
5. Application Number	5.
6. Foreign/PCT Application Re:	6.
7. Other: Assignee	7. Bristol-Myers Squibb Pharma Company

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: March 10, 2005


Brian J. Hubbard
Registration No. 45,873

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



UNITED STATES PATENT AND TRADEMARK OFFICE

 Sem/SW
 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/770,380	02/02/2004	1646	900	DM-6999(BMS-2594)		6	1

CONFIRMATION NO. 9680 ✓

 23914
 STEPHEN B. DAVIS
 BRISTOL-MYERS SQUIBB COMPANY
 PATENT DEPARTMENT
 P O BOX 4000
 PRINCETON, NJ 08543-4000

FILING RECEIPT



OC000000014976983

Date Mailed: 01/18/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Milind Rajopadhye, Westford, MA;
 Thomas David Harris, Salem, NH;
 Edward H. Cheesman, Lunenburg, MA,

Should read:

Assignment For Published Patent Application

(Dupont Pharmaceuticals Company)

"Bristol-Myers Squibb Pharma Company"

Power of Attorney: The patent practitioners associated with Customer Number 23377.

Domestic Priority data as claimed by applicant

 This application is a DIV of 09/466,588 12/17/1999 PAT 6,794,518
 which claims benefit of 60/112,829 12/18/1998

Please correct.

Foreign Applications

If Required, Foreign Filing License Granted: 05/01/2004 ✓

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US10/770,380

Reel/Frame
012607/0038

Projected Publication Date: To Be Determined - pending completion of Missing Parts

For parent case
recording

Non-Publication Request: No

Early Publication Request: No

Title

Vitronectin receptor antagonist pharmaceuticals ✓

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).